530549 Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Shilpa Medicare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹935.80 |
| 52 Week High | ₹959.95 |
| 52 Week Low | ₹313.55 |
| Beta | 0.65 |
| 11 Month Change | 17.78% |
| 3 Month Change | 34.21% |
| 1 Year Change | 146.98% |
| 33 Year Change | 62.37% |
| 5 Year Change | 213.08% |
| Change since IPO | 41,185.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 530549 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 7.2% | -0.2% | 0.3% |
| 1Y | 147.0% | 40.5% | 27.3% |
Return vs Industry: 530549 exceeded the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: 530549 exceeded the Indian Market which returned 27.3% over the past year.
Price Volatility
| 530549 volatility | |
|---|---|
| 530549 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 530549 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 530549's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,007 | Vishnukanth Bhutada | www.vbshilpa.com |
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. Its APIs also include nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate.
Shilpa Medicare Limited Fundamentals Summary
| 530549 fundamental statistics | |
|---|---|
| Market cap | ₹76.38b |
| Earnings (TTM) | ₹610.83m |
| Revenue (TTM) | ₹12.16b |
133.0x
P/E Ratio6.7x
P/S RatioIs 530549 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 530549 income statement (TTM) | |
|---|---|
| Revenue | ₹12.16b |
| Cost of Revenue | ₹4.45b |
| Gross Profit | ₹7.72b |
| Other Expenses | ₹7.11b |
| Earnings | ₹610.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.04 |
| Gross Margin | 63.45% |
| Net Profit Margin | 5.02% |
| Debt/Equity Ratio | 21.1% |
How did 530549 perform over the long term?
See historical performance and comparison